-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FFF8QTpP/DXYVIdyXatVIoSfkPlo6riBGBeUX2kPpMVuUIzXv3hpUaGWIcsoCeF7 fv/D8uIN77TPbmqbO43/mQ== 0000950103-05-001754.txt : 20050722 0000950103-05-001754.hdr.sgml : 20050722 20050722132542 ACCESSION NUMBER: 0000950103-05-001754 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20050722 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20050722 DATE AS OF CHANGE: 20050722 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-29630 FILM NUMBER: 05968188 BUSINESS ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 BUSINESS PHONE: 1264333455 MAIL ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 8-K 1 jul2205_8k.htm feb0305_8-K
   
   
UNITED STATES 
SECURITIES AND EXCHANGE COMMISSION 
 
Washington, D.C. 20549 
   
   
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 

Date of Report (Date of earliest event reported):   July 22, 2005

Shire Pharmaceuticals Group plc
(Exact name of registrant as specified in its charter)
 
England and Wales
(State or other jurisdiction of incorporation)

0-29630   98-0359573
(Commission File Number)   (IRS Employer Identification No.)

Hampshire International Business Park, Chineham, Basingstoke,
Hampshire RG24 8EP England
(Address of principal executive offices)                                                (Zip code)

Registrant’s telephone number, including area code                    44 1256 894 000

 
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Item 8.01. Other Events

     Shire Pharmaceuticals Group plc has issued the press releases attached as Exhibit 99.01 and Exhibit 99.02 which are incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

    (c)   Exhibits. The following exhibits are filed herewith:
     
99.01   Press Release dated July 22, 2005
99.02   Press Release dated July 22, 2005
 





SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


SHIRE PHARMACEUTICALS GROUP PLC
     
By: /s/ A C Russell
 
  Name: Angus Russell
  Title: Chief Financial Officer

Dated: July 22, 2005

 






EXHIBIT INDEX
   
Number Description
   
99.01 Press Release dated July 22, 2005
99.02 Press Release dated July 22, 2005
 
 



EX-99.1 2 ex9901.htm
  EXHIBIT 99.01
Hampshire International Business Park
Chineham Basingstoke
Hampshire RG24 8EP
United Kingdom
Tel +44 (0)1256 894000
Fax +44 (0)1256 894708
www.shire.com
   
Press Release  
   

22 July 2005

Shire Pharmaceuticals Group plc (the "Company")

Application has been made to the UK Listing Authority and the London Stock Exchange for a listing of 120,000 ordinary shares of 5p each in the Company to be admitted to the Official List.

These shares, ranking pari passu in all respects with the existing shares in issue, have been issued pursuant to the exchange of certain Exchangeable Shares in Shire Acquisition Inc., in accordance with the terms of the Merger Agreement with BioChem Pharma Inc.


T May

Company Secretary

For further information please contact:   
       
Investor Relations  Cléa Rosenfeld (Rest of the World)  + 44 1256 894 160 
       
  Brian Piper (North America)  + 1 484 595 8252 


Notes to editors

Shire Pharmaceuticals Group plc

Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal diseases. Shire has operations in the world’s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.

For further information on Shire, please visit the Company’s website: www.shire.com.


Registered in England 2883758 Registered Office as above



 GRAPHIC 3 logo.jpg GRAPHIC begin 644 logo.jpg M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_ MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"``_`*0#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BBBB@`H MHHH`**^2_P!J+]NG]DW]C'1X=6_:0^-W@WX<7-]92W^C>%;FZGUGQYXAM8C+ M'Y^@>!-`@U3Q9JEFUQ"UHVIV^DG2;:Z*Q7E_;9+#\%O&/_!U=^RO8:MJ:_J'@7P8VIJTT<:3VFG6NL>+KR-98V9X8;P6MTTGEP20 M1&1GB^IR;@KBOB"E]8RC(\=B\/=*.)<(8?#3;;C:EB<5.A0JN+34U2J3&]%6(ABLAUJQTSQ+JGG*=GF6\GAF%`& M_=W+XS7V+\"?^"F/_!23]HKP&?C9\%_V&?V8OC+\,K>9'O\`PG\,OVX_!NL_ M%.QADA6X&DZDB^&;C0-!\4+!OF_L'7QINJL$$9TY"\;MZ6*\->,,!A_K69Y? MA,JH.HJ4*F9YSDV!C4JNW+3C+$8^"4I7]US<(-W2E=.V5+-\!7DX4*TJ\XQY MY1HT:]248W2U4:;=US:P5YJTO=O%I?T"T5^)WB+_`(+S_L6_#'X=_#/Q=\== M'^-7P@\6^/KCX@Z'K/PNUCX;ZEK/B_X>>-?A5XH'A#QYX0\7+IDHM[:^T[5W MM[C39U(75=%OK#4?)LY9I;*W^F/V)/\`@J=^R3_P4#\4>./!_P"SGKGC?5=; M^'N@:;XE\1Q>+/`VJ^$X(]*U347TNUDL[F_=X[N;[6FV6!"KHC+)@KG;Y&+X M/XGP.#Q&88O(\QHX#"SJ4Z^-EAY/"TY4J[PTW[>/-2E!5U[)5(2E3E+X)233 M.B&.P=2I&E#$T959I.-+VD54?-#VB7LVU-/D?-RM*26Z1^C-%%%?-G4%%?$/ M[;?_``4'_9P_X)]^&?`WBW]HW5?%FE:/\1-=U/P[X:D\*>$M0\63RZGI&GQ: MG>I>0:>Z-9PK:S(TJ>*_ M!_@V;QYK4'BKP'JOA2SC\/0:WH_A^26WO;]WBN+H:EKNGH+5`)#$\DH^6)J] MNGPWGU7*I9[2RG'5,G@IRGF,*$Y82,:=7V%1NJERI0JITY/9233V9SO%895O MJ[KTE7NE[%SBJEW%37N7YM8M2VVU/TLHHHKQ#H"BBB@`HHHH`****`"BBB@` MKX__`&W/VU_@O^PI\#O%/QB^+OB;0[&\L]"\13_#WP/>ZQ!IFO?%'Q?H^DRZ MA8^#O#,1BNKF2YOKDV=O?ZE'97-GH5K=KJ.I&.W4;_DG]N+_`(*>+\'O'T?[ M)7[(?@*7]IO]N;Q);QM8?#+127\*?#'3;F#S)?%GQ4\01SVUGI<.FPS6EXN@ MO>VDLJ7-K_:M_HZ7NFKJ7R7IG_!-+XW^#O@3\9_VT?VC;C2?VU?^"G@^%GB' MQ9\,-"^(-G9>+/A'\*/&6DZ7?:EX>\%_"3P/'O[0LIF6.RU&73[2SFU MR"U33M/TW3[B^@OOM\GX8PU-9=F/$V(C@,%CL1AHY?ECJPHYEF\*]2,(5WSZ M99D^K=?-\3%KV:E]3HXF;YH>=7QUK:.EAVHM\MMZU>VL:, M=$[>UE!-7_E3^-OPB^-7[0FL^)OVXO\`@HY\8+_X)CXM7::U\,O`FMZ#?>)? MCY\7/#=S.'T#0_@;\(+J_P##Z:)\*_#UG?V.AZ3XT\9:UX;\-VUM-!=Z;%XK MO)KD77[D_![_`(-R?&GB_P"%/@;6(?B1I'[(.NZCX?.I:G8R>$Y/C?\`'VYE M\10Q7'V/Q]\47\1_#WPUX0U/2+"1](N?"WP<\'>&=%07%Y::]K?C2XMK?5J_ MDG^*WQZ^-7QF^*$_Q:^,/Q`\5^//B;'J%K.WB#Q=>W%]J&G2:5=_:+#2[*TN M@+?1])TB=?)T_0+&VM-,TN%%L[2RMX(UB7^UC]D#_@YV_9M\=^&+#1OVNO"' MB+X+_$"QM[&UU#Q5X1T^?QC\/?$,XBV7NL)96QC\2>&/,G42#1TM/$B(DA*: MB`HA7^C^.:7B!E64Y7+A.C1J>QE5CC<)E>$PU:CEN'I4J%+`X3`8#$TI2QE! MQ=;VU:KA\1656G2J8>A@*;]FOB\KJY/7Q.(6.::VU74+& M&YTN*VG-ZGR7_P`$M/\`@H#XV_X)[_M1^$/B/9:QJ'_"G_%>JZ/X8^/O@Z%E MEL/$WP^FN9K>751:2GR_^$A\#MJ-QXF\-WL+072W%M=Z0UR-+UO5;>Z_T`;3 M]LC_`()L_P#!0#X:>+_@79_M"_"/XC>%OB_X9U7P3KG@74_$TW@CQ/K>G:Y; M?8KBVTK2/$Z^&O$JZI"]Q%)IU[H]O]MLM2BM[K3YTNH(I%^5)/\`@W/_`."6 M$B/&_P`&O&!21&1Q_P`+@^*`RK@JPR/%0(R"1D$'TKY#+_%2A_8F-R#Q/RK- MIXS$^VP]14\HHX9XG`U(12E5P]:K@HT<50K*;IU:%&,8RC1J0Y*U-R?H5.'F ML90QF2XBA"E3<)^]7E449QEJH2A&IS0G#XE*3O>4=F?@=_P<[^`]"\$?&#]F MJ[T2\DU-OB'HOQO^)NK:K)':1M?W_BWQMX=EM%06<%O"]KI7A^TT/0+"9T:Z MN-/TBUN+Z>YO9;BXD[;_`(-0O^3A/VL?^R->"_\`U-Y:;_P=3Z19>'_BK^Q7 MH.FI)'IVB?!CQSI&GQS32W$J66F^(_#MG:I+<3O)-/(L$,:O-,[RRL"\CL[$ MG\E/^"9W_!1[4/\`@G#IG[47C3P;X:@\2_%SXI_#KPMX"^&`U5!)X:\.ZK%X MAO-4U/Q;X@@#I)J,&AV21OI^C1M&FIZG<6JWGA\16VC^$-+AO,N=/M](BM;>4-MM8R&4'U[ M]B+_`(+5_MK?LE_%+PMKGBGXP?$/XX?!U-3@A\>?"?XC>*K_`,5VFJ>')V:. M_P#^$4U'Q%)J5YX1U^S60W^F7NCS6MO<7MM!:ZO!?Z;)<6LGYU6\!LY^HU,1 M@L]RK'XNG"3>$IPJTZ+%]O" ME6PN(H0FTE5J(_%&H7OB;1-2UJ'5(-;T*VTF&UM(]-O+-[>6"2!II))3( MKHP55!!-?.'_``1^_P""+GQ,_P"":_QW^)'Q<\;?&CP9\2=.\W/C+PEXF74I[G4=0NX9+9(/#D]J8$C60RW,4@<+&RMY!_P<'? MMH_%_P"&/[,'[&7QB_91^-?C[X9Z3\9_$.H^(H/$'@/Q!J?AB[\3^#-=^'NB M^*?#/]HMIUQ#)-;M;:E!>Q6\SNL,LS$?-DU\#?\`!#3]NC]L'X[_`!'_`&R] M-^,7[1OQ;^)-CX*_8G^*'CGPE9^,/&FM:Y;^'_&&E:[X2M]-\1:5%?74R6>K M6<-W558!VS.5Y7QM4\+\0Z.<9=A^'K8ZC6RFM@;Y@K9K.CB*; MQ#H.49RQ7--)U.:,'R7C9).K6RS_`%@IIT*TL.H_MJ_M"M8OJ>DF_^T_%#Q/Y#6INK M?[5YY-^P\DP[_-R&&PMD'D']*/\`@JK_`,%ZOCY\?/BIXL^%W[(_Q)\1?"#] MG;PEJ>I>'=.\5^!-1O?#WC3XN-9W2P2^+K[Q%!%8^(="\/7S03)H?AW3Y[%9 M])G%SKR75W<);6&%?P*XEI9C@<%3Q^7UZ&)IXJKB"4[*$5& M\I2:2NDDW9/_`$!J*_A<_P"""?\`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`8#$PR_),LJ_P3C<14JXFEEF%FZ=:I#V^)K1^*AA M8S47R?\`3VM)\D&VN17EORM?I[_P37_X)S^!?V"?A9=QW6I7'Q&_:"^)<\/B MKXX_&;Q$5U'Q-XF\5WUG:/J6CV&K7$9U"+PCI>H)=-I-E-,\T\MQA0Z M]:6&@Z[X2\6ZCIERL,ZM':&77M$L;$W1P#+=P6P.ZX56^?P]+-^->(J=&>)I MULVSC$.$:V+J>QH^T5.4H4KQA)4:484U1H4J<.2"5.E"*C9+JD\-EF#E)0=/ M#X:#DU!.4K7]Z3ZSDV^:4FVY.[;;/CO_`(*7?\&[7PN_:C\5^+OCI^S#XET[ MX)_&'Q*SZMK_`((N]-A_X51XS\0,,WFK-;:?#%J'A/7=;D`FU34M.:YTRYO6 MN=3N]$N=2O;J[D_E9_:'_P""-O\`P41_9JM)]7\:?L^>(O%7ARWDE1_$?PL; M_A85AB(C,G]GZ-%_PDJQ%2K"6304C&[E_E8C]=OV+_\`@X[_`&I_&W[4_P`# M_!7[2>H_#BP^"7C+QS8>$O'>IZ5X1T[2;O2+7Q)!E07K,K*"I_N+CDM[RWCFADANK6YB26*6-DGM[B"5`\C MVGC3P=XGOKSQ#K?@S1`SVMYKOPSN[^]232M2LHIQ>SZ(;A='US[-Y-U#%=M; MW]K_`'C?M9_L3?LO?M7?"OQAX*^.'PX\&W.G7V@ZEY7C0Z7INF>(O!EQ%;2S MQ>)](\0I##:-(OVX7+3B(1QRQW&8))5/^41J=K;V.IZE8V=_'JMG9:C? M6=IJD2&*+4[6UNI8+;4HHF^:.*_AC2[CC;YHTF5&Y!K]/X7XFR/Q8RC-L%F. M2>R6#^KTL5A\1*&)II8R-=T,1@L6J5*=*M"6&JNZA3J49*G*,IJ3:\''8+%\ M.8BA7P^+YXU'+E:3@WR@>._B'^PWX MW\*:E!K'A?QC\"_%_BGPWJ]JVZVU30?$&N^&M6TC4+=N\-Y87=O<1GKLD&>: M^9_^#;G]ECX=?M#_`+;?B?QI\3M"MO$^B_L^_#.;Q]X=T/44AN=(N/'VL^(- M+\,^'KW5]/GCDBU&WTC3;OQ%JEE!*IC@UNUTJ_(,MI#CY5_;XN_%][^PU_P2 M&G\:/6O/S*E6X<\(,UP>#Q4G4RREFF5T\73ERS MG3AQ%B"IU8W6SY9 M)-=+I']J7CCX;^!OB1X*U_X=^-O"^B^(?!GB;1[W0M9\/ZEIUK<:;=Z9?VTE MI/`;:2)HD_.O\H'_@HK_R M?Y^VM_V=5\?/_5H>)Z^&^C[B:_U[B3".I)X>6$P.(=-MN/MH5J]-5$GM)PJ2 MC)JW,E'FOR1MZO&,8^PP<^5<_M:D>:RYN7D3Y;VO:^MKVOK:Y^MW_!1'Q+JW MBS_@AM_P1YU;6[E[N^@N_B/X?2>1F9_[-\(_VQX3T6%F[>"P;]7_943^=FW(%O`2<`0QDD]`-B\FO[\O\`@B7_ M`,$>_P!G'P#^S%\*/VFOCA\.=&^*/QL^-_@O2OB!9Q>/=+M=9T3X>>$O%$9U M7PIIGAO0[^W:UM-5OO#<^E:GK6K7,,VJ?;;ZYT^&YCT^&*`?P"MQIK8_Y\3_ M`.B#7^P!\"((;7X'_!JVMXHX+>W^%/P[@@@B18XH88O"&CQQ11HH"I'&BJB( MH"JH```%>=X[9YF.59+E."R_%5L)'-<;BUBZN'J2I59T,%2HM8=U(-35.K4Q M49U(Q:YO8QC*\92B].%<+0KXO&5JM.-26'4/9*:4E&56=2\TGIS)4[)M.RD[ M6Z_QM?\`!SWKOPN^%^O?LZ?LU?";X?\`@_P%/K>CZK\;?B5+X3T#2M#EU^VM M+[5O`_PPM=3?38();J#2)C\4+B""Y#Q)+J*S1`2*QK\]O^"&GQD_8,_9K^._ MCO\`:"_;/\8?V-XB\$:'H^D_`O0[CPEJ/BG3FUKQ&=;C\8>,)5L;&]%KJWA[ M2[+2])T9I?+`3Q-JD\8>:")X?M7_`(.KOAIXATO]K+]G7XOS6[GPIXU_9]D^ M'FG787,:^(/AO\0_%OB'6;5V`^61M.^)^A31@GYU\S:/W;FOA'_@C;_P34^! M_P#P4J\2_'#P-\2/C#XM^&OC7X;Z-X-\3^$]#\+V^ASR^)_#>K7FOZ9XJU&1 M=8LKMF'AW48/"\#BU*[!K\;3`@H1W9"\HCX/X6IFF89CA\MQ.7REFN88"A1J5:4TL/0J., M*5J=#GC:_+&+7O58K3W]KMZ_UMZ]_P`%[/\`@DKXIT74O#?B7XQC7M`UBRN- M-U71=7^&/BG4-,U"PNX7M[FSN[*YT>2WGMYX)'BDCD1E9&92,&O\_P`_:OLO M@78_M(?&>#]F;5;C6O@#+XZU>^^%-Y=6U[:2Q^#]5:/5-/THP:FB7ZQZ";V7 M08VO$\^6/35E=I-_F/\`V'_\0IO[.?\`T+?A%HNM6*W<$=U:F\TS48[>]M? MM-K+#=0">&,RVTT,\8:*6-V^=X*S[PPX3Q&,>09UQ)C'C:-.-?"8C!XK%TOW M,TX8B-'#991E&K3]I*G[1MQ4*DXM-N+7;FF$SS,:=*.(PF$I.G/FA46(I1EK M&SC=S2LW[S6NJ5K6/VI_X(;?M#>)_P!I'_@FI\`?%'C:Z2_\6^`[;7_@UK%^ M&+S7]M\+]6F\.>%KV^Y/O%OCO3_';ZCX?U6VN;W6%TO1M2TW3[[PRJZ3 M-::==>'&B<1EYDOFO$G;>NQ"OY[XJJX&OQ)GM?+(RA@*^:8VMA:&/Q"953REF89O_!$+_@IE^RU MX<_8O^%?[+_QB\=6'P4^,?P,M=?\,:SH/Q!M[GPU9Z]8:CXR\2Z_I&L:+>7< M$<+2?V?JMO;:S;7AM[F#4XYI`)([A"G]+C*KJR.JNCJ5=&`965@0RLI!#*P) M!!!!!((Q7F%_\#_@OJMS+>:G\(OACJ-W.S//=7O@+PM=7$[N06>::?2GDE=B MH):1F;CK7O8?B[`U^$,/P?G.5XBMA\#F%3,-VX2494TFO9)OCJ9?5CF,\RPU:"J5*"P]6C6@W3G%.+4E.$E*$ER1 M^S/9K9V7$6O[6?[.6HP)/A5\,_^"@?[/WQE_9[\<>&_&&F?#OQII5MI%IXNU/1UTF6;5[6 MZCU?1?%?@V*^9[F63PUK>G:?>Q3WUK:+%?#0/4:!X>TC1@>,?\`,.L[;MQ].*ZFOEHXW#8+$4L5E4,;A\5AZU*OA<56 MQ5.53#U:-2%6G5A"CAZ*52,H:.4YQL[\MU<[_9SJ0E3Q#I5(3C*%2$8249QD MG%Q?-.3LTVFM/7H?Y1_[:G[`O[17["7Q5\0?#KXO^#]5;2M,N?.\-?$O2-.O MI_`_C#1)BKZ?K.F:TD+6MI/*K"*[TJ\FBOK"^BN;9DE2)+B7Z>_9Q_X+B_\` M!1#]F3P-I/PV\&?%NS\3>#=`L+?2]`TSXB^'=.\9SZ)IUH"EK8:=J6JK)>P6 M<$>(XH#*X5`!DX&/]*?QCX%\%_$/1;KPYX[\*>'O&&A7L$]MPUFQD MAN87@G`@OX)TC9XG9/-C"2J#E'5@"/RU\;?\$+O^"8_CC4[S5;C]G#1O#MU? MSRW-ROA'5=3T*W>:5P[NMO%--&F2"`J!54,P4#-?O>%\9N',ZP%+!<;\,1QM M2DH2=2AA\+CL+5K124J\<-BY4IX2<[7:I5*RU<4U"R/DY\-8S"UIU<=;*Z=VS^)O\`:2_X+??\%#?VG_`VM?#;QQ\7+/PY MX(\1Z?-I7B+1_A[X=T[P:^MZ9<#;=:?J>H:6L=Y<6-U'F.XM_,598R58XR#Y MS_P3G_X)E?'?_@H%\8/#GA;PYX;U[PO\(;2_T^^^)/Q;O]+N+70M!\*_:%:^ M30KN]A2TUOQ%?VT4]MH]C:&XB6[*2WK10(1)_=Y\/O\`@B#_`,$S?AUJ^GZY MIO[-7AO7=2TN:*YL9_%U[J/B!8KB$QM%*8+F=()61XUDQ+&Z%RQ9"&(K]1?# M?A;PSX.TFVT+PEX>T7PQHMFBQVNDZ!I=EI&G0(BA%$5G80P0*0J@%@FXXR23 MS6./\9E>$/AQ^SSXD\#>%M/W+FUT#PIJWA?0]*A=L*9 M94LK*'SYB-\TQ>60EW8GI_\`@U!96_:$_:QVLK8^#7@K."#C/C>7&<'C.#CZ M&O["/C/^RC^SA^T3J6A:Q\VM MD[NOE0W-Q;PS2J`=SQJ<\4?!G]E#]F_]G?4]:UGX'_!GP+\,-5\16%OIFN7_ M`(2T>/3+C5-/M+@W5M:7CH[>;##56CRZ-76J5CZ#K_)^_X**R1_\-^?MKC>F1^U7\?0?F7@CXH>)P0> M>H/!'8U_K`U\9^*O^">'[$'C?Q-XA\9^+?V8?A)X@\4^+-;U3Q'XDUW4O#,, M^H:SKNM7LVHZKJE],9`9;N_OKB>ZN),#?+*[8&:\?PSXYP/`^-S3%8[!8O&P MQ^%H4*<<)*C&5.5*M*HY3]M**::=ERN]UKH[KISS*JN:TJ%.E4ITW2J2FW4Y MK-2CRI+EC+\3^)O]NYE'_!"3_@C]EE&?$WQNQD@9_P"*D\7=,GGJ*G_X-V75 MOBI^WIM96(_X)]_&`_*03_R,?@KL,U_<;XC_`&,/V5?%WP[\#_"3Q-\!_AUK M?PT^&LNH3^`O!6H:''/H/A2;5I9I]2DT:S+[;5KR:XGDG*D[VE<\9I?A?^QC M^RM\%+WQ'J/PG^!'PZ\`WWB[PS?>#?$UUX;T..PFUOPMJ?IU MW-:6TDT!P&:%#GBOJ:OBOE53AC.:9OCZ5?VF&]E2IYEGM;-:<) MKGY^>G2JJE-Q3BZD;Q;B[KCI9#7IYCA,:ZU)PP^'H490M/FDZ6#6&DX^[:S: MYE=IVW5]#_)!>1/[-8;TS]A(QN&<^0>.M?[!'P/_`.2*_"#_`+)=\/\`_P!1 M/2:^9/\`AV-_P3]V[/\`ADGX+;=NW;_PBD&-N,8_UO3'%?<&GZ?9:586.EZ; M;16>G:;9VVGV%G`NR"TLK.%+>UMH4_@B@@CCBC7^%$`[5X_B=XBY=QU0R>E@ M,OQN">6UL?5JO%SH2518N&$C!0]C.33@\/+FYK)J4;=;=&29/6RN>*E5JTZB MQ'L[*GS7BZ;J-WYHK?VG3:W6^GY1?\%DO^">5S_P4/\`V4I?!7@^XL=.^,OP MPUX_$+X37VH92TU#4HK">PU_P=>SKAK>S\6Z1)]FBG),5KK5EHM[.DD-HZ'_ M`#Z?A1\2_P!K+_@FE^T=8>/-`TKQ-\&?C/X(?5]#NM)\8^'9H[74M/O8C9:Q MHVJ:7J,0T_Q!HMR!&Y\E[JR:YM[6[@F:2WC%? MCW\(?!7Q)TJ8Q,KZ_HUM+J=L]N28'M-8A6+4[?RBQ*QQW0AR?FC;BL^!/$W_ M`%9RZOP]G.6QSGA_$SJN5"]/VV'IXIU MD&:Y']>KT\9AJ[PN,I)6J).TW!ITVW%J490MRJ2O=635HJ_\0.O?\'/O[>FJ M>%[C1-*\'?!CPYKLMMY$7C"TT&^O[Z&7!5KE=)U"XDTCS&!+!1#LC<*4&`0? MS#^`G[/_`.UC_P`%6/VL3%!<>)?%GC7XL>+9]4^)7QAUNPU"Z\,>$[18&N-3 MUK7=2B1;*"'2M+M5MM(T*&XCN+CRK#3+.)(V$D?]Y5I_P0K_`."7]I=07)_9 MF\/72P2K*MG>:EJL]DVPY6.2#[2N^-<`!"_08)-?I9\+O@[\*_@EX7L?!7PD M^'_A3X>>%M.@CMK71O"NC6>E6PBB+F,3O;QK/>.AD?$UY-/,`Q'F8P*^KGXJ M\&Y!A<6^!^$_J.9XRG*G+%XFAAJ%*CI>G.7LZV*K8B-.HE46%O1H.<4W+H<3 MR',<94I/-F^%]'1@OVF\-I&9-0UC4'4`3:KKNJ2WNLZK<'YKC4+ZYF M/+T5[-17X!7KUL37K8G$5)UJ^(JU*U:M4DY5*M6K-SJ5)R>LISG)RDWJVVSZ 5R,8PC&,4HQBE&*6RBE9)>22LC__9 ` end EX-99.2 4 ex9902.htm
  EXHIBIT 99.02
Hampshire International Business Park
Chineham Basingstoke
Hampshire RG24 8EP
United Kingdom
Tel +44 (0)1256 894000
Fax +44 (0)1256 894708
www.shire.com
   
Press Release  
   

22 July 2005


Shire Pharmaceuticals Group plc (the “Company”)

The Company announces that it was notified on 21 July 2005 under Sections 198 to 202 of the Companies Act that FMR Corp. and its direct and indirect subsidiaries and Fidelity International Limited and its direct and indirect subsidiaries, both being non-beneficial holders, held solely for investment purposes, in aggregate 24,450,766 ordinary shares of £0.05p each in the capital of the Company. These holdings represent 4.96 per cent of the issued ordinary share capital of the Company.

T May
Company Secretary

For further information please contact:   
       
Investor Relations  Cléa Rosenfeld (Rest of the World)  + 44 1256 894 160 
       
  Brian Piper (North America)  + 1 484 595 8252 


Notes to editors

Shire Pharmaceuticals Group plc

Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal diseases. Shire has operations in the world’s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.

For further information on Shire, please visit the Company’s website: www.shire.com.

Registered in England 2883758 Registered Office as above

 -----END PRIVACY-ENHANCED MESSAGE-----